Adult Hepatocellular Carcinoma
10
1
1
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
10.0%
1 terminated out of 10 trials
88.9%
+2.4% vs benchmark
0%
0 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (10)
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery